Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 4/2007

01-04-2007 | Article

Phenotype-specific inhibition of the vascular smooth muscle cell cycle by high glucose treatment

Authors: X.-L. Zheng, S.-G. Yuan, D.-Q. Peng

Published in: Diabetologia | Issue 4/2007

Login to get access

Abstract

Aims/hypothesis

Diabetes accelerates the development of atherosclerosis, which critically involves the proliferation of vascular smooth muscle cells (SMCs). However, how high glucose treatment regulates SMC proliferation is controversial. Considering the established SMC heterogeneity, we hypothesised that glucose treatment may have distinct effects on proliferation of the various phenotypic SMCs.

Materials and methods

We tested this possibility using cloned spindle-shaped and epithelioid SMCs and laser scanning cytometry.

Results

Our results showed that glucose treatment significantly inhibited the serum-independent proliferation of epithelioid SMCs, but had no effect on the proliferation of spindle-shaped cells either with or without serum stimulation. Furthermore, glucose treatment inhibited DNA synthesis, as detected by bromodeoxyuridine (BrdU) incorporation, and increased the production of reactive oxygen species in epithelioid SMCs. The inhibition of BrdU incorporation by glucose treatment was mimicked by glucosamine and phorbol 2,13-dibutyrate, a protein kinase C (PKC) activator, and reversed by azaserine, an inhibitor of the hexosamine pathway. In addition, the inhibitory effects of glucose treatment were blocked by GF 109203X (a PKC inhibitor) and PD98058 (a MAPK/ERK kinase, MEK inhibitor), and by knockdown of MEK1 by small interfering RNA (siRNA). The addition of either GF 109203X or PD98058 also reduced the phosphorylation of MAP kinase induced by glucose treatment.

Conclusions/interpretation

Glucose treatment inhibits the proliferation of epithelioid, but not spindle-shaped, vascular SMCs through the activation of PKC and the MAP kinase pathway, suggesting that the effects of hyperglycaemia on vascular disease depend on the phenotype of SMCs involved.
Literature
1.
Ross R, Glomset JA (1973) Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 180:1332–1339PubMedCrossRef
2.
Dzau VJ, Braun-Dullaeus RC, Sedding DG (2002) Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 8:1249–1256PubMedCrossRef
3.
Yamamoto M, Acevedo-Duncan M, Chalfant CE, Patel NA, Watson JE, Cooper DR (2000) Acute glucose-induced downregulation of PKC-betaII accelerates cultured VSMC proliferation. Am J Physiol, Cell Physiol 279:C587–C595PubMed
4.
Begum N, Ragolia L (2000) High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation. Am J Physiol, Cell Physiol 278:C81–C91PubMed
5.
Yasunari K, Kohno M, Kano H, Yokokawa K, Minami M, Yoshikawa J (1999) Antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose. Circulation 99:1370–1378PubMed
6.
Morishita R, Higaki J, Hayashi SI et al (1997) Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor. Diabetologia 40:1053–1061PubMedCrossRef
7.
Yasunari K, Kohno M, Kano H, Yokokawa K, Horio T, Yoshikawa J (1996) Possible involvement of phospholipase D and protein kinase C in vascular growth induced by elevated glucose concentration. Hypertension 28:159–168PubMed
8.
Yasunari K, Kohno M, Kano H, Yokokawa K, Horio T, Yoshikawa J (1995) Aldose reductase inhibitor prevents hyperproliferation and hypertrophy of cultured rat vascular smooth muscle cells induced by high glucose. Arterioscler Thromb Vasc Biol 15:2207–2212PubMed
9.
Hiroishi G, Kobayashi S, Nishimura J, Inomata H, Kanaide H (1995) High d-glucose stimulates the cell cycle from the G1 to the S and M phases, but has no competent effect on the G0 phase, in vascular smooth muscle cells. Biochem Biophys Res Commun 211:619–626PubMedCrossRef
10.
Natarajan R, Gonzales N, Xu L, Nadler JL (1992) Vascular smooth muscle cells exhibit increased growth in response to elevated glucose. Biochem Biophys Res Commun 187:552–560PubMedCrossRef
11.
Sakakibara F, Hotta N, Koh N, Sakamoto N (1993) Effects of glucose treatment and epalrestat on sorbitol and myo-inositol metabolism in cultured rabbit aortic smooth muscle cells. Diabetes 42:1594–1600PubMed
12.
Xia P, Kramer RM, King GL (1995) Identification of the mechanism for the inhibition of Na+,K(+)-adenosine triphosphatase by hyperglycemia involving activation of protein kinase C and cytosolic phospholipase A2. J Clin Invest 96:733–740PubMed
13.
Jacot TA, Clemmons DR (1998) Effect of glucose on insulin-like growth factor binding protein-4 proteolysis. Endocrinology 139:44–50PubMedCrossRef
14.
Williams B, Gallacher B, Patel H, Orme C (1997) Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 46:1497–1503PubMed
15.
Park SH, Marso SP, Zhou Z, Foroudi F, Topol EJ, Lincoff AM (2001) Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation 104:815–819PubMed
16.
Suzuki LA, Poot M, Gerrity RG, Bornfeldt KE (2001) Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. Diabetes 50:851–860PubMed
17.
Dahlfors G, Chen Y, Gustafsson B, Arnqvist HJ (2000) Inhibitory effect of diabetes on proliferation of vascular smooth muscle after balloon injury in rat aorta. Int J Exp Diabetes Res 1:101–109PubMed
18.
Bornfeldt KE, Arnqvist HJ, Capron L (1992) In vivo proliferation of rat vascular smooth muscle in relation to diabetes mellitus insulin-like growth factor I and insulin. Diabetologia 35:104–108PubMedCrossRef
19.
Schiller NK, McNamara DB (1999) Balloon catheter vascular injury of the alloxan-induced diabetic rabbit: the role of insulin-like growth factor-1. Mol Cell Biochem 202:159–167PubMedCrossRef
20.
Hao H, Gabbiani G, Bochaton-Piallat ML (2003) Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler Thromb Vasc Biol 23:1510–1520PubMedCrossRef
21.
Walker LN, Bowen-Pope DF, Ross R, Reidy MA (1986) Production of platelet-derived growth factor-like molecules by cultured arterial smooth muscle cells accompanies proliferation after arterial injury. Proc Natl Acad Sci USA 83:7311–7315PubMedCrossRef
22.
Gui Y, Zheng XL (2003) Epidermal growth factor induction of phenotype-dependent cell cycle arrest in vascular smooth muscle cells is through the mitogen-activated protein kinase pathway. J Biol Chem 278:53017–53025PubMedCrossRef
23.
Blaes N, Bourdillon MC, Daniel-Lamaziere JM, Michaille JJ, Andujar M, Covacho C (1991) Isolation of two morphologically distinct cell lines from rat arterial smooth muscle expressing high tumorigenic potentials. In Vitro Cell Dev Biol 27A:725–734PubMed
24.
Gui Y, Zheng XL (2006) 2-methoxyestradiol induces cell cycle arrest and mitotic cell apoptosis in human vascular smooth muscle cells. Hypertension 47:271–280PubMedCrossRef
25.
Kamentsky LA (2001) Laser scanning cytometry. Methods Cell Biol 63:51–87PubMed
26.
Darzynkiewicz Z, Bedner E, Li X, Gorczyca W, Melamed MR (1999) Laser-scanning cytometry: a new instrumentation with many applications. Exp Cell Res 249:1–12PubMedCrossRef
27.
Zheng XL, Gui Y, Du G, Frohman MA, Peng DQ (2004) Calphostin-C induction of vascular smooth muscle cell apoptosis proceeds through phospholipase D and microtubule inhibition. J Biol Chem 279:7112–7118PubMedCrossRef
28.
Robinson JP, Carter WO, Narayanan PK (1994) Oxidative product formation analysis by flow cytometry. Methods Cell Biol 41:437–447PubMed
29.
Rosenkranz AR, Schmaldienst S, Stuhlmeier KM, Chen W, Knapp W, Zlabinger GJ (1992) A microplate assay for the detection of oxidative products using 2′,7′-dichlorofluorescein-diacetate. J Immunol Methods 156:39–45PubMedCrossRef
30.
McClain DA, Paterson AJ, Roos MD, Wei X, Kudlow JE (1992) Glucose and glucosamine regulate growth factor gene expression in vascular smooth muscle cells. Proc Natl Acad Sci USA 89:8150–8154PubMedCrossRef
31.
Sayeski PP, Kudlow JE (1996) Glucose metabolism to glucosamine is necessary for glucose stimulation of transforming growth factor-alpha gene transcription. J Biol Chem 271:15237–15243PubMedCrossRef
32.
Porte D Jr, Schwartz MW (1996) Diabetes complications: why is glucose potentially toxic? Science 272:699–700PubMedCrossRef
33.
Toullec D, Pianetti P, Coste H et al (1991) The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 266:15771–15781PubMed
34.
Sasaguri T, Kosaka C, Hirata M et al (1993) Protein kinase C-mediated inhibition of vascular smooth muscle cell proliferation: the isoforms that may mediate G1/S inhibition. Exp Cell Res 208:311–320PubMedCrossRef
35.
Fukumoto S, Nishizawa Y, Hosoi M et al (1997) Protein kinase C delta inhibits the proliferation of vascular smooth muscle cells by suppressing G1 cyclin expression. J Biol Chem 272:13816–13822PubMedCrossRef
36.
Wang S, Desai D, Wright G, Niles RM, Wright GL (1997) Effects of protein kinase C alpha overexpression on A7r5 smooth muscle cell proliferation and differentiation. Exp Cell Res 236:117–126PubMedCrossRef
37.
Lorenz K, Lohse MJ, Quitterer U (2003) Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 426:574–579PubMedCrossRef
38.
Marais R, Light Y, Mason C, Paterson H, Olson MF, Marshall CJ (1998) Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science 280:109–112PubMedCrossRef
39.
Kolch W, Heidecker G, Kochs G et al (1993) Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 364:249–252PubMedCrossRef
40.
Sozeri O, Vollmer K, Liyanage M et al (1992) Activation of the c-Raf protein kinase by protein kinase C phosphorylation. Oncogene 7:2259–2262PubMed
41.
Konishi A, Berk BC (2003) Epidermal growth factor receptor transactivation is regulated by glucose in vascular smooth muscle cells. J Biol Chem 278:35049–35056PubMedCrossRef
42.
Askari B, Renard CB, Bornfeldt KE (2002) Regulation of smooth muscle cell accumulation in diabetes-accelerated atherosclerosis. Histol Histopathol 17:1317–1328PubMed
43.
Du XL, Edelstein D, Rossetti L et al (2000) Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 97:12222–12226PubMedCrossRef
44.
Inoguchi T, Sonta T, Tsubouchi H et al (2003) Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 14:S227–S232PubMedCrossRef
45.
Herbert JM, Clowes M, Lea HJ, Pascal M, Clowes AW (1996) Protein kinase C alpha expression is required for heparin inhibition of rat smooth muscle cell roliferation in vitro and in vivo. J Biol Chem 271:25928–25935PubMedCrossRef
46.
Nishizuka Y (1995) Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 9:484–496PubMed
47.
Mischak H, Goodnight JA, Kolch W et al (1993) Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem 268:6090–6096PubMed
48.
Gruber JR, Ohno S, Niles RM (1992) Increased expression of protein kinase C alpha plays a key role in retinoic acid-induced melanoma differentiation. J Biol Chem 267:13356–13360PubMed
49.
Wolf G, Reinking R, Zahner G, Stahl RA, Shankland SJ (2003) Erk 1,2 phosphorylates p27(Kip1): functional evidence for a role in high glucose-induced hypertrophy of mesangial cells. Diabetologia 46:1090–1099PubMedCrossRef
50.
Bornfeldt KE, Campbell JS, Koyama H et al (1997) The mitogen-activated protein kinase pathway can mediate growth inhibition and proliferation in smooth muscle cells. Dependence on the availability of downstream targets. J Clin Invest 100:875–885PubMedCrossRef
Metadata
Title
Phenotype-specific inhibition of the vascular smooth muscle cell cycle by high glucose treatment
Authors
X.-L. Zheng
S.-G. Yuan
D.-Q. Peng
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0543-6

Other articles of this Issue 4/2007

Diabetologia 4/2007 Go to the issue

Article

Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study

Article

Sphingosine kinase 1 participates in insulin signalling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice

Article

Effect of type 2 diabetes mellitus on exercise intolerance and the physiological responses to exercise in peripheral arterial disease

Article

Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects

Article

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus

Short Communication

Deletion of the gene encoding the islet-specific glucose-6-phosphatase catalytic subunit-related protein autoantigen results in a mild metabolic phenotype
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits